Tsumura : Supplementary Materials The Third Quarter of the Term Ending March 31, 2023

TSE.4540

Supplementary Materials

The Third Quarter of the Term Ending March 31, 2023

February 3, 2023

TSUMURA & CO.

Consolidated Statements of Income	・・・・・	1
investments, R&D expenses, etc.	・・・・・	1
Growth rates of 129 prescription Kampo products ・・・・・	1
Product sales	・・・・・	2
Consolidated Balance Sheets	・・・・・	3
Consolidated Statements of Cash Flows	・・・・・	3
Quarterly data
Consolidated Statements of Income	・・・・・	4
Consolidated Balance Sheets	・・・・・	4
Consolidated Statements of Cash Flows ・・・・・	5
Product sales	・・・・・	5

Consolidated Statements of Income											(Million yen)
		FY 3/2022 3Q	FY 3/2023 3Q	Year-on-year			Full-year forecast for FY 3/2023
		cumulative	cumulative
		Amount	% of sales	Amount	% of sales	Amount		%	Amount	% of sales	Year-on-year	Year-on-year
			(Amount)	(%)
Net sales		98,382	100.0%	107,076	100.0%	8,694		8.8%	138,500	100.0%	8,953	6.9%
Domestic		91,317	92.8%	96,346	90.0%	5,029		5.5%	124,200	89.7%	4,632	3.9%
Overseas		7,065	7.2%	10,729	10.0%	3,664		51.9%	14,300	10.3%	4,321	43.3%
Cost of sales		47,997	48.8%	54,517	50.9%	6,519		13.6%	69,800	50.4%	6,718	10.7%
Gross profit on sales		50,384	51.2%	52,559	49.1%	2,175		4.3%	68,700	49.6%	2,234	3.4%
Selling, general and administrative expenses		31,554	32.1%	34,836	32.5%	3,281		10.4%	47,900	34.6%	3,811	8.6%
Operating profit		18,829	19.1%	17,723	16.6%	(1106)		(5.9)%	20,800	15.0%	(1,576)	(7.0)%
Ordinary profit		21,074	21.4%	21,410	20.0%	335		1.6%	21,200	15.3%	(4,704)	(18.2)%
Profit attributable to owners of parent		15,389	15.6%	15,875	14.8%	486		3.2%	15,000	10.8%	(3,836)	(20.4)%
Investments, R&D expenses, etc.											(Million yen)
		FY 3/2022 3Q	FY 3/2023 3Q	Year-on-year			Full-year forecast for FY 3/2023
		cumulative	cumulative
		Amount	% of sales	Amount	% of sales	Amount		%	Amount	% of sales	Year-on-year	Year-on-year
			(Amount)	(%)
Investments		7,037	7.2%	11,010	10.3%	3,973		56.5%	22,000	15.9%	9,902	81.9%
Capital investments		6,716	6.8%	7,935	7.4%	1,219		18.2%	17,500	12.6%	6,043	52.7%
R&D expenses		5,193	5.3%	5,628	5.3%	434		8.4%	7,600	5.5%	286	3.9%
Advertising expenses		481	0.5%	637	0.6%	156		32.6%	1,000	0.7%	(104)	(9.5)%
Depreciation		6,497	6.6%	7,578	7.1%	1,081		16.6%	9,800	7.1%	1,056	12.1%
Personnel expenses		24,151	24.5%	25,326	23.7%	1,174		4.9%	34,800	25.1%	1,897	5.8%

※From the current consolidated fiscal year, the "acquisition of property, plant and equipment" has been changed to "investment amount of property, plant and equipment and software, etc." and the comparative figures have been rearranged.

Growth rates of 129 prescription Kampo products

	FY 3/2016	FY 3/2017	FY 3/2018	FY 3/2019	FY 3/2020	FY 3/2021	FY 3/2022	FY 3/2023 1Q	FY 3/2023	FY 3/2023
									2Q	3Q
Amount	2.3%	1.9%	2.4%	2.7%	1.8%	1.1%	8.1%	6.7%	6.8%	5.3%
Number of items with higher yen sales	68	95	63	83	66	82	110	101	106	99

1

Product sales

							(Million yen)
				FY 3/2022	FY 3/2023	Year-on-	Year-on-
Rank		No.	Product Name	year	year
	3Q	3Q
				(Amount)	(%)
1	☆	100	Daikenchuto	7,334	7,482	147	2.0%
2	G	41	Yokukansan	5,655	6,096	441	7.8%
3	☆	54	Hochuekkito	5,678	5,687	9	0.2%
4	☆	43	Rikkunshito	5,548	5,644	96	1.7%
5	G	17	Goreisan	4,111	4,821	710	17.3%
6	G	24	Kamishoyosan	3,752	3,935	183	4.9%
7		68	Shakuyakukanzoto	3,692	3,847	155	4.2%
8	☆	107	Goshajinkigan	2,687	2,633	(54)	(2.0)%
9		114	Saireito	2,559	2,572	13	0.5%
10		29	Bakumondoto	2,455	2,463	8	0.3%
16	G	108	Ningin'yoeito	1,488	1,624	135	9.1%
17	G	137	Kamikihito	1,332	1,600	267	20.1%
24	☆	14	Hangeshashinto	1,052	1,078	26	2.5%
			Total of "Drug Fostering" Program formulations	22,301	22,527	225	1.0%
			Total of Growing formulations	16,340	18,078	1,738	10.6%
			Total of 129 prescription Kampo products	87,293	91,941	4,648	5.3%

☆ ："Drug Fostering" Program formulations

1. ：Growing formulations

Regarding Growing prescriptions, Ninjinyoeito and Kamikihito have been added as new growth drivers from the current consolidated fiscal year, and the lineup has been changed in order to aim for write ups in treatment guidelines by building evidence.

2

Consolidated Balance Sheets			(Million yen)
	As of March 31	As of December 31	Increase /
	2022	2022	decrease
Total assets	350,981	400,958	49,977
Current assets	229,420	270,962	41,542
Liquid assets	122,431	155,586	33,154
Inventories	92,751	101,079	8,327
Non-current assets	121,561	129,995	8,434
Property, plant and equipment	90,040	94,857	4,817
Total liabilities	92,871	121,276	28,404
Current liabilities	45,875	43,696	(2,179)
Non-current liabilities	46,996	77,580	30,583
Total net assets	258,109	279,682	21,572

Consolidated Statements of Cash Flows			(Million yen)
	FY 3/2022	FY 3/2023	Year-on-year
	3Q	3Q
Cash flows from operating activities	17,815	8,930	(8,884)
Cash flows from investing activities	(7,510)	(12,425)	(4,914)
Cash flows from financing activities	(5,192)	24,456	29,648
Cash and cash equivalents at the end of the quarter	67,070	93,711	26,640

3